Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,058 recalls, newest first

Class II · Moderate risk

GaviLyteTM - C PEG-3350

Failed Stability Specification; Out of specification for Osmolarity

Terminated Stability / shelf life Novel Laboratories, Inc. d.b.a LUPIN NDC 43386-060-19 D-0726-2021
Class II · Moderate risk

Ethosuximide Oral Solution USP 250 mg/5 mL

Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.

Terminated cGMP deviation PAI Holdings, LLC. dba Pharmaceutical Associates Inc NDC 0121-0670-16 D-0723-2021
Class II · Moderate risk

Nystatin Oral Suspension

Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.

Terminated cGMP deviation PAI Holdings, LLC. dba Pharmaceutical Associates Inc NDC 0121-0868-16 D-0721-2021
Class II · Moderate risk

Venlafaxine Tablets

Presence of Forein Tablets/Capsules; Venlafaxine Tablets, USP 37.5 mg found in bottles labeled as Venlafaxine Tablets, USP, 50 mg

Terminated Labeling / mix-up Sun Pharmaceutical Industries INC NDC 16714-657-01 D-0703-2021
Class II · Moderate risk

GoodSense Aller.Ease

Failed Impurities/Degradation Specifications; Out of specification result obtained for impurity A during stability testing.

Terminated Impurity / degradation Perrigo Company PLC NDC 0113-0571-30 D-0357-2022
Class II · Moderate risk

CVS Allergy Relief

Failed Impurities/Degradation Specifications; Out of specification result obtained for impurity A during stability testing.

Terminated Impurity / degradation Perrigo Company PLC NDC 69842-698-39 D-0356-2022

Recalls by year